The 4th Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium
King Abdulaziz Medical City in cooperation with the Saudi Oncology Society (SOS) and the Arab Medical Association Against Cancer (AMAAC)
Four Seasons Hotel, Riyadh, Kingdom of Saudi Arabia
06-07 January 2010 |
|
DAY ONE (1) - 06 JANUARY 2010 - WEDNESDAY |
|
Time |
Topic |
Speaker(s) |
|
| |
|
|
0800 - 0900 |
Registration and Breakfast / Exhibition |
|
0900 - 0910 |
Welcome Remarks |
...Dr. Omalkhair Abulkhair
...Chairperson, Scientific Committee |
|
0910 - 0940 |
Breast Cancer Prevention
Chairpersons: Dr. Mohammed Mohideen, Dr. Sami Khatib & Dr. Abdulrahman Jazieh
|
|
|
0910 - 0935 |
Abstract # ES 2-1: Advances in Preventive Therapy |
...Prof. Jack Cuzick, Phd. |
| |
|
|
0935 - 0940 |
Discussion |
|
|
0940 - 1105 |
Controversies in Adjuvant Chemotheraphy
Chairpersons: Dr. Mohammed Mohideen, Dr. Sami Khatib & Dr. Abdulrahman Jazieh
|
|
|
|
|
0940 - 1000 |
Abstract # CS 1-1: Are there groups of patients who don't benefit from chemotherapy? |
...Dr. Naghi Saghir |
|
|
|
1000 - 1020 |
Abstract # CS 1-2: What are the best and most highly effective chemotherapy regimens? |
...Dr. Kathy Pritchard |
|
|
|
1020 - 1040 |
Abstract # 32: Systemic MiRNA levels as novel breast cancer biomaker |
...Dr. Arun Banu |
| |
|
| Abstract # 75: The TEAM trial pathology study idetifies potential prognostic and predictive biomaker models for postmenopausal patients treated with endocrine therapy |
...Dr. Arun Banu |
| |
|
| Abstract # 78: Tumor Ki67 proliferationindex within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders |
...Dr. Arun Banu |
| |
|
|
1040 - 1050 |
Abstract # 74: Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) store and comparison with the GHI recurrence score-results from TransATAC |
...Prof. Jack Cuzick, Phd |
| |
1055 - 1105 |
Discussion |
|
|
1105 - 1120 |
Break |
|
|
1120 - 1215 |
Update on Hormonal Therapy for Breast Cancer
Chairpersons::Dr. Mahmoud Shaheen Al-Ahwal, Dr. Abdulwahab Andejani, & Dr. Ali Shanqeeti |
|
|
|
|
1120 - 1130 |
Abstract # 11: Five years of Examestane as initial therapy compared to 5 years of Tamoxifen followed by Examestane: the TEAM Trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer |
...Dr. Kathy Pritchard |
|
|
|
1130 - 1140 |
Abstract # 12: Disease-related outcome with long term follow-up: An updated analysis of the Intergroup Examestane Study (IES) |
...Dr. Kathy Pritchard |
|
|
|
1140 - 1150 |
Abstract # 13: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA 17 Trial |
...Dr. Kathy Pritchard |
|
|
|
1150 - 1200 |
Abstract # 16: Adjusting for selective crossover in analyses of Letrozole (Let) versus Tamoxifen (Tam) in the BIG 1-98 Trial |
...Dr. Kathy Pritchard |
| |
|
|
1200 - 1215 |
Discussion |
|
| |
|
|
1215 - 1315 |
Lunch and Prayer Time / Exhibition |
|
|
|
